SCHEMBL4854630

SCHEMBL4854630

CCOC(=O)c1c(SC)nc(-c2ccc(SC)cc2)n(-c2ccc(C)cc2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
ALDH1A1 P00352 12/20 0.43
MAPT P10636 5/20 0.43
HPGD P15428 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TARBP2 Q15633 1/20 0.40
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
CYP2C19 P33261 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4862562 0.92 GABRA2 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL4857041 0.92 GABRA2 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL4861276 0.85 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1GAAHTT
SCHEMBL5821476 0.80 ALDH1A1 (0.43) ALDH1A1MAPTHPGDNPSR1GAA
SCHEMBL5821480 0.80 ALDH1A1 (0.41) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL6141870 0.78 HTT (0.49) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL14223770 0.77 ALDH1A1 (0.43) SIRT2SIRT1ALDH1A1MAPTNPSR1
SCHEMBL7245244 0.76 MAPK13 (0.40) KMT2AALDH1A1HPGDNPSR1L3MBTL1
SCHEMBL7250847 0.76 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1L3MBTL1GAA
SCHEMBL2951048 0.74 ALDH1A1 (0.48) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US claimed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US claimed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP MEN1 917/4885KMT2A 4298/4885SIRT2 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.